JS Cleiftie is NextRNA’s Chief Business Officer and Chief Financial Officer. He is responsible for Business & Corporate Development and Finance. He joins us with 20 years of experience in Business and Corporate Development, Venture Capital, and Drug Development in Pharma and Biotech.
Most recently, JS served as Chief Business Officer of Erytech Pharma, a NASDAQ-listed clinical-stage oncology company, where he was responsible for Business Development & Licensing, External Innovation, and New Product Planning.
Prior to that, he was associate Vice-President, Global Business Development & Licensing at Sanofi, where he led and supported numerous sell-side and buy-side transactions across multiple therapeutic areas and development stages.
Before joining Sanofi, JS was a Principal at Innoven Partners, a life sciences and technology venture capital firm, where he executed numerous equity investments in private biotech and medtech companies.
He started his career in drug development in the US as a research scientist with Aventis (now Sanofi) in immunotherapy and gene therapy for cancer.
JS earned an MS in Biological & Medical Sciences and a MS in Immunology from the University of Paris V, and received his MBA from Cornell University.